Lck, a member of the Src kinase family, is a non-receptor tyrosine kinase involved in immune cell activation, antigen recognition, tumor growth, and cytotoxic response. The enzyme has usually been linked to T lymphocyte activation upon antigen recognition. Lck activation is central to CD4, CD8, and NK activation. However, recently, it has become clearer that activating the enzyme in CD8 cells can be independent of antigen presentation and enhance the cytotoxic response. The role of Lck in NK cytotoxic function has been controversial in a similar fashion as the role of the enzyme in CAR T cells. Inhibiting tyrosine kinases has been a highly successful approach to treating hematologic malignancies. The inhibitors may be useful in treating other tumor types, and they may be useful to prevent cell exhaustion. New, more selective inhibitors have been documented, and they have shown interesting activities not only in tumor growth but in the treatment of autoimmune diseases, asthma, and graft vs. host disease. Drug repurposing and bioinformatics can aid in solving several unsolved issues about the role of Lck in cancer. In summary, the role of Lck in immune response and tumor growth is not a simple event and requires more research.
Lck是Src激酶家族成员，是一种非受体酪氨酸激酶，参与免疫细胞活化、抗原识别、肿瘤生长及细胞毒性反应。该酶通常与抗原识别后的T淋巴细胞活化相关，其激活对CD4、CD8及NK细胞的活化至关重要。然而近期研究表明，CD8细胞中Lck的激活可不依赖于抗原呈递过程，并能增强细胞毒性反应。Lck在NK细胞毒性功能中的作用存在争议，这种争议性与其在CAR-T细胞中的作用相似。抑制酪氨酸激酶已成为治疗血液系统恶性肿瘤的高效策略，此类抑制剂不仅可能适用于其他肿瘤类型的治疗，还有望用于预防细胞耗竭。目前已报道的新型高选择性抑制剂不仅在抑制肿瘤生长方面表现出独特活性，在自身免疫性疾病、哮喘及移植物抗宿主病的治疗中也显示出潜在价值。药物重定位与生物信息学方法有助于解决Lck在癌症领域中若干尚未明确的作用机制问题。总之，Lck在免疫应答和肿瘤生长中的作用并非单一机制，仍需进一步深入研究。
Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event
肿瘤(癌症)患者之家